Membranous Nephropathy: Current Understanding in The Light of New Advances

Basit Öğe Kaydı
dc.contributor.authorOzer, Hakan
dc.contributor.authorBaloglu, Ismail
dc.contributor.authorFervenza, Fernando C.
dc.contributor.authorTurkmen, Kultigin
dc.date.accessioned2024-02-23T14:41:18Z
dc.date.available2024-02-23T14:41:18Z
dc.date.issued2023
dc.departmentNEÜen_US
dc.description.abstractMembranous nephropathy is the most common cause of primary nephrotic syndrome in adults. The most important mech-anism in its pathogenesis is loss of immune tolerance. New developments in membranous nephropathy are mostly related to the diagnosis and treatment of the disease, and until recently, the gold standard method in diagnosis was a kidney biopsy. In recent years, many membranous nephropathy-associated antigens and antibodies have been identified. The increased availability of these biomarkers is beneficial in predicting the treatment response, determining the treatment plan, and eliminating the necessity of kidney biopsy in the diagnosis of membranous nephropathy. Because of both the difference in treatment responses and the treatment-related side effects, membranous nephropathy treatment should be individualized. In addition, it is recommended to make a treatment plan by calculating the risk of progressive kidney fail-ure of the disease. Parallel to the changes in diagnosis and follow-up, treatment plans in membranous nephropathy have undergone severe changes in recent years. As the autoimmunity targets in the pathogenesis of the disease become clearer, treatment has turned to more specific therapies that are more selective in targeting antibody-producing cells, such as rituximab. This article described the new developments in the pathogenesis, diagnosis, and treatment of membranous nephropathy.en_US
dc.description.sponsorshipScientific Research Fund of the Karadeniz Technical University [THD-2018-7309]en_US
dc.description.sponsorshipFunding study was financed by the Scientific Research Fund of the Karadeniz Technical University (THD-2018-7309) .en_US
dc.identifier.doi10.5152/turkjnephrol.2023.22123421
dc.identifier.issn2667-4440
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-85154052131en_US
dc.identifier.urihttps://doi.org/10.5152/turkjnephrol.2023.22123421
dc.identifier.urihttps://hdl.handle.net/20.500.12452/16797
dc.identifier.volume32en_US
dc.identifier.wosWOS:000977236600002en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherAvesen_US
dc.relation.ispartofTurkish Journal Of Nephrologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAnti-Phospholipase A2 Antibodyen_US
dc.subjectMembranous Nephropathyen_US
dc.subjectNephrotic Syndromeen_US
dc.subjectRituximaben_US
dc.titleMembranous Nephropathy: Current Understanding in The Light of New Advancesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu